Waters raises annual profit forecast on biosciences growth
The lab equipment maker increased its 2026 adjusted profit forecast to a range of $14.40 to $14.60 per share after exceeding quarterly revenue estimates. Growth was driven by strong demand for drug development tools and the performance of its recently acquired biosciences and diagnostics unit.
Xurve View
洞察:
Xurve View
WATERS CORP raised its 2026 profit forecast to a range of $14.40 to $14.60 per share following a quarterly earnings beat. The lab equipment maker increased its outlook from a previous high of $14.50 per share after shares climbed 12.7% to $340.13 in midday trading. The update signals that the integration of a major biosciences acquisition is accelerating growth faster than the market anticipated.
